Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NYH817G and NYH100P in Advanced Solid Tumors
NCT04262739Phase 1Unknown
- Sponsor
- Haim Bio
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gossypol acetate and NYH100P in solid tumor (advanced stage) (3 arms), sponsored by Haim Bio. Primary endpoints: Adverse event up to 2 years and Disease control rate up to 2 years. Status: unknown.
02
Drugs
gossypol acetateNYH100P
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04262739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262739.